Abbott Labs might be an M&A target; Pharma overruled as U.S. trade rep nixes 'worst offender' status for India;

@FiercePharma: Takeda wins $70M from Japan to bump up H5N1 vaccine production. More | Follow @FiercePharma

@TracyStaton: ICYMI: Allergan to propose to Shire again, but does Irish beauty want to get engaged? Story | Follow @TracyStaton

@EricPFierce: Reckitt Benckiser abandons talks with Merck. Sounds like Bayer is left standing in battle for OTC unit. | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's issue of FiercePharmaMarketing with stories from @TracyStaton, @CarlyHFierce and @EmilyWFierce. Report | Follow @CarlyHFierce

> Could Abbott Laboratories ($ABT) become the next merger target in the pharma industry's M&A wave? If the company doesn't boost returns, then maybe so. Report

> India dodged a bullet--and pharma lobbyists suffered a defeat--when the U.S. Trade Rep decided not to slap a "worst offender" tag on the country in its latest scorecard on intellectual property protections. Report

> Consolidation in the U.S. pharma business is hurting medium-size Indian drugmakers as newly dominant players force generic drug prices down. Report

> U.S.-based Alexza Pharmaceuticals ($ALXA) said its partner Medivir Ferrer rolled out its new inhaled antipsychotic drug, Adasuve, in four Nordic countries. Report (sub. req.)

> The onset of Obamacare has boosted consumer spending on health services, with purchases soaring by 9.9% at an annualized rate. Report

Medical Device News

@FierceMedDev: Boston Scientific rolls out next-gen stent system in Japan. Article | Follow @FierceMedDev

@VarunSaxena2: Parkinson's is a hot area for drug delivery; many companies are trying to deliver established drugs in new ways to treat "off" episodes. | Follow @VarunSaxena2

@EmilyWFierce: Endo will pay $830M to resolve a majority of its vaginal mesh cases. Story | Follow @EmilyWFierce

@MichaelGFierce: Imaging technique maps transdermal drug migration. Story from FierceDrugDelivery | Follow @MichaelGFierce

> HeartWare warns about battery safety in its ventricular assist device. Story

> Hologic narrows its losses on the crawl toward growth. News

Biotech News

@FierceBiotech: Can anything prevent $PFE's megamerger with $AZN? More | Follow @FierceBiotech

@JohnCFierce: Merrimack heads to the FDA after scoring positive PhIII for pancreatic cancer. Article | Follow @JohnCFierce

@DamianFierce: AstraZeneca's "mild-mannered Swede" stands up to Pfizer and dismisses Big Pharma's sudden embrace of big deals. More | Follow @DamianFierce

@EmilyMFierce: Looking to sales growth, Merck rolls out vaccine adherence plan. Story | Follow @EmilyMFierce

> Amid Zohydro controversy, Teva, Purdue and Pfizer race ahead with new pain drugs. Article

> VC Lightstone lands $172M with an eye on biotech startups. More

> Shire bags an early-stage fibrosis drug in $75M Fibrotech buyout. News

Pharma Manufacturing News

> New York men indicted for selling counterfeit and unapproved drugs in U.S. More

> Hospira makes progress on plant problems, reports improved financials. Report

> Taro expands Canada plant with help from Ontario. More

> Boehringer Ingelheim works a deal with Saudi firms to package its products. Story

> WuXi PharmaTech expands cell therapy manufacturing in U.S. Article

Vaccines News

> Looking to sales growth, Merck rolls out vaccine adherence plan. Report

> Experts: MERS vaccine is possible--but is it worth it? Story

> Need for malaria vaccine grows as climate change threatens disease spread. More

> Sanofi turns out positive PhIII data in quest for dengue blockbuster. Article

> Pentaxim supply delay weighs down Sanofi earnings. News

And Finally... Another reason to drink coffee: It may cut your risk of Type 2 diabetes. Report (sub. req.)

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.